SG11201807940XA - Production of antigen-specific t-cells - Google Patents
Production of antigen-specific t-cellsInfo
- Publication number
- SG11201807940XA SG11201807940XA SG11201807940XA SG11201807940XA SG11201807940XA SG 11201807940X A SG11201807940X A SG 11201807940XA SG 11201807940X A SG11201807940X A SG 11201807940XA SG 11201807940X A SG11201807940X A SG 11201807940XA SG 11201807940X A SG11201807940X A SG 11201807940XA
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- antigen
- international
- specific
- ste
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 9
- 239000000427 antigen Substances 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 230000005291 magnetic effect Effects 0.000 abstract 3
- 108091008874 T cell receptors Proteins 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 230000001745 anti-biotin effect Effects 0.000 abstract 2
- 229960002685 biotin Drugs 0.000 abstract 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 2
- 235000020958 biotin Nutrition 0.000 abstract 2
- 239000011616 biotin Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000005298 paramagnetic effect Effects 0.000 abstract 2
- 229920002307 Dextran Polymers 0.000 abstract 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 abstract 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 abstract 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical group [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 abstract 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309234P | 2016-03-16 | 2016-03-16 | |
| PCT/US2017/022663 WO2017161092A1 (en) | 2016-03-16 | 2017-03-16 | Production of antigen-specific t-cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807940XA true SG11201807940XA (en) | 2018-10-30 |
Family
ID=59850933
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807940XA SG11201807940XA (en) | 2016-03-16 | 2017-03-16 | Production of antigen-specific t-cells |
| SG10202008210XA SG10202008210XA (en) | 2016-03-16 | 2017-03-16 | Production of antigen-specific t-cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202008210XA SG10202008210XA (en) | 2016-03-16 | 2017-03-16 | Production of antigen-specific t-cells |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200291381A1 (ja) |
| EP (1) | EP3445399A4 (ja) |
| JP (1) | JP7016098B2 (ja) |
| KR (1) | KR102470979B1 (ja) |
| CN (1) | CN109475620A (ja) |
| AU (1) | AU2017233035B2 (ja) |
| CA (1) | CA3017615A1 (ja) |
| IL (1) | IL261710A (ja) |
| RU (2) | RU2745319C2 (ja) |
| SG (2) | SG11201807940XA (ja) |
| WO (1) | WO2017161092A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| AU2018337960A1 (en) * | 2017-09-20 | 2020-04-30 | Neximmune, Inc. | Cell compositions comprising antigen-specific T cells for adoptive therapy |
| AU2018346765A1 (en) * | 2017-10-06 | 2020-04-16 | Oncotherapy Science, Inc. | Screening of T lymphocytes for cancer-specific antigens |
| JP2021527419A (ja) * | 2018-06-20 | 2021-10-14 | ダンマークス テクニスク ユニバーシテットＤａｎｍａｒｋｓ Ｔｅｋｎｉｓｋｅ Ｕｎｉｖｅｒｓｉｔｅｔ | 免疫細胞操作用の安定化されたｍｈｃ分子を有するスカフォールド |
| WO2020061256A1 (en) * | 2018-09-19 | 2020-03-26 | FUJIFILM Cellular Dynamics, Inc. | Protein l for activation and expansion of chimeric antigen receptor-modified immune cells |
| CN109136276A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种rfft2细胞的构建方法 |
| WO2020097466A1 (en) | 2018-11-08 | 2020-05-14 | Neximmune, Inc. | T cell compositions with improved phenotypic properties |
| EP4110350A4 (en) * | 2020-02-27 | 2024-04-03 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | COBRA1/NELF-B USED AS AN EFFECTIVENESS ENHANCER OF CD8+ T CELL THERAPY |
| EP4172352A4 (en) * | 2020-06-26 | 2024-07-03 | Univ Johns Hopkins | ADAPTIVE NANOPARTICLE PLATFORMS FOR HIGH-THROUGHPUT DETECTION AND MULTIPLICATION OF ANTIGEN-SPECIFIC T CELLS |
| KR20230118166A (ko) * | 2020-12-11 | 2023-08-10 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료를 위한 방법 및 물질 |
| WO2023060217A1 (en) * | 2021-10-08 | 2023-04-13 | Baylor College Of Medicine | Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers |
| WO2023144275A1 (en) * | 2022-01-28 | 2023-08-03 | Katholieke Universiteit Leuven | Actuation of organoids by magnetic nanoparticles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2311920C2 (ru) * | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| JP2006524991A (ja) * | 2003-05-08 | 2006-11-09 | エクサイト セラピーズ インコーポレーティッド | 抗原特異的ｔ細胞の作製および単離の方法 |
| AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| CN102168066A (zh) * | 2011-01-31 | 2011-08-31 | 浙江大学 | 体外诱导乙型肝炎病毒特异性细胞毒性t淋巴细胞的方法 |
| JP6482461B2 (ja) * | 2012-07-13 | 2019-03-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 投与に関する形質導入ｔ細胞の適合性の評価方法 |
| CN105431523B (zh) * | 2013-03-14 | 2020-08-21 | 约翰·霍普金斯大学 | 纳米级人工抗原呈递细胞 |
| EP3052085B1 (en) * | 2013-10-03 | 2019-07-03 | University of Maryland, Baltimore | Nanoparticle based artificial antigen presenting cell mediated activation of nkt cells |
| US10066265B2 (en) * | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| KR20160016725A (ko) * | 2014-08-05 | 2016-02-15 | 주식회사 유영제약 | 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포 |
-
2017
- 2017-03-16 EP EP17767506.3A patent/EP3445399A4/en active Pending
- 2017-03-16 KR KR1020187029819A patent/KR102470979B1/ko active IP Right Grant
- 2017-03-16 AU AU2017233035A patent/AU2017233035B2/en active Active
- 2017-03-16 CA CA3017615A patent/CA3017615A1/en active Pending
- 2017-03-16 RU RU2018136203A patent/RU2745319C2/ru active
- 2017-03-16 SG SG11201807940XA patent/SG11201807940XA/en unknown
- 2017-03-16 RU RU2021107053A patent/RU2021107053A/ru unknown
- 2017-03-16 WO PCT/US2017/022663 patent/WO2017161092A1/en active Application Filing
- 2017-03-16 CN CN201780030022.4A patent/CN109475620A/zh active Pending
- 2017-03-16 JP JP2018568171A patent/JP7016098B2/ja active Active
- 2017-03-16 SG SG10202008210XA patent/SG10202008210XA/en unknown
- 2017-03-17 US US16/084,121 patent/US20200291381A1/en not_active Abandoned
-
2018
- 2018-09-12 IL IL261710A patent/IL261710A/en unknown
-
2023
- 2023-02-21 US US18/111,975 patent/US20230332131A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3017615A1 (en) | 2017-09-21 |
| EP3445399A4 (en) | 2019-10-30 |
| SG10202008210XA (en) | 2020-10-29 |
| AU2017233035B2 (en) | 2021-08-05 |
| KR20190026645A (ko) | 2019-03-13 |
| US20200291381A1 (en) | 2020-09-17 |
| EP3445399A1 (en) | 2019-02-27 |
| KR102470979B1 (ko) | 2022-11-24 |
| CN109475620A (zh) | 2019-03-15 |
| IL261710A (en) | 2018-10-31 |
| RU2018136203A3 (ja) | 2020-06-22 |
| JP2019513412A (ja) | 2019-05-30 |
| US20230332131A1 (en) | 2023-10-19 |
| RU2745319C2 (ru) | 2021-03-23 |
| AU2017233035A1 (en) | 2018-11-01 |
| RU2018136203A (ru) | 2020-04-16 |
| WO2017161092A1 (en) | 2017-09-21 |
| RU2021107053A (ru) | 2021-08-24 |
| JP7016098B2 (ja) | 2022-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807940XA (en) | Production of antigen-specific t-cells | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201808633RA (en) | Anti-human vista antibodies and use thereof | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201805137XA (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| SG11201809617RA (en) | Intracellular delivery of biomolecules to induce tolerance | |
| SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201805507UA (en) | Retractable heat source for aerosol generating article | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201908127WA (en) | Method for producing multispecific antibodies | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201909501TA (en) | Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro | |
| SG11201810694WA (en) | Use of biomarkers in determining susceptibility to disease treatment | |
| SG11201903032SA (en) | Methods and compositions related to nk cell and anti-pdl1 cancer therapies | |
| SG11201806401YA (en) | G protein-coupled receptor (gpcr) modulation by imipridones | |
| SG11201807250PA (en) | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |